Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Antisense anti-MDM2 oligonucleotides as a novel therapeutic approach to human breast cancer: in vitro and in vivo activities and mechanisms.

Clinical cancer research : an official journal of the American Association for Cancer Research - 1 Nov 2001

Wang H, Nan L, Yu D, Agrawal S, Zhang R

Abstract excerpt

The mouse double minute 2 (MDM2) oncogene has been suggested as a target for cancer therapy. It is amplified or overexpressed in many human cancers, including breast cancer, and MDM2 levels are associated with poor prognosis of several human cancers, including breast cancer, ovarian cancer, osteosarcoma, and lymphoma. In the present study, we investigated the functions of MDM2 oncogene in the growth of breast...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Camptothecin
Share to Cyclin-Dependent Kinase Inhibitor p21

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Cyclins

Share to DNA, Antisense

Share to Doxorubicin

Share to Drug Synergism

Share to Fluorouracil

Share to Proto-Oncogene Proteins c-mdm2

Source

Identifiers

PMID: 11705884

Genes

MDM2

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Antisense anti-MDM2 oligonucleotides as a novel therapeutic approach to human breast cancer: in vitro and in vivo activities and mechanisms.PMID 11705884Read ↗

Novel Antisense Anti-MDM2 Mixed-Backbone Oligonucleotides: Proof of Principle, In Vitro and In Vivo Activities, and MechanismsSemantic proximity Read ↗

MDM2 oncogene as a target for cancer therapy: An antisense approach.Semantic proximity Read ↗

Radiosensitization by antisense anti-MDM2 mixed-backbone oligonucleotide in in vitro and in vivo human cancer models.Semantic proximity Read ↗

Anti-Tumor Efficacy of a Novel Antisense Anti-MDM2 Mixed-Backbone Oligonucleotide in Human Colon Cancer Models: p53-Dependent and p53-Independent MechanismsSemantic proximity Read ↗

Antisense therapy targeting MDM2 oncogene in prostate cancer: Effects on proliferation, apoptosis, multiple gene expression, and chemotherapySemantic proximity Read ↗

MDM2 Oncogene as a Novel Target for Human Cancer TherapySemantic proximity Read ↗

Antisense anti-MDM2 mixed-backbone oligonucleotides enhance therapeutic efficacy of topoisomerase I inhibitor irinotecan in nude mice bearing human cancer xenografts: In vivo activity and mechanisms.Semantic proximity Read ↗

Ubiquitous induction of p53 in tumor cells by antisense inhibition of MDM2 expression.Semantic proximity Read ↗

Enhanced tumor cell kill by combined treatment with a small-molecule antagonist of mouse double minute 2 and adenoviruses encoding p53.Semantic proximity Read ↗

The role of the MDM2/p53 axis in antitumor immune responsesSemantic proximity Read ↗

The growth arrest function of the human oncoprotein mouse double minute-2 is disabled by downstream mutation in cancer cells.Semantic proximity Read ↗

Role of MDM2 Overexpression in Doxorubicin Resistance of Breast CarcinomaSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.